Literature DB >> 26712160

Targeted Transthoracic Acoustic Activation of Systemically Administered Nanodroplets to Detect Myocardial Perfusion Abnormalities.

Thomas R Porter1, Christopher Arena2, Samer Sayyed2, John Lof2, Robin R High2, Feng Xie2, Paul A Dayton2.   

Abstract

BACKGROUND: Liquid core nanodroplets containing condensed gaseous fluorocarbons can be vaporized at clinically relevant acoustic energies and have been hypothesized as an alternative ultrasound contrast agent instead of gas-core agents. The potential for targeted activation and imaging of these agents was tested with droplets formulated from liquid octafluoropropane (C3) and 1:1 mixtures of C3 with liquid decafluorobutane (C3C4). METHODS AND
RESULTS: In 8 pigs with recent myocardial infarction and variable degrees of reperfusion, transthoracic acoustic activation was attempted using 1.3 to 1.7 MHz low (0.2 mechanical index [MI]) or high MI (1.2 MI) imaging in real time (32-64 Hertz) or triggered 1:1 at end systole during a 20% C3 or C3C4 droplet infusion. Any perfusion defects observed were measured and correlated with delayed enhancement magnetic resonance imaging and postmortem staining. No myocardial contrast was produced with any imaging setting when using C3C4 droplets or C3 droplets during low MI real-time imaging. However, myocardial contrast was observed in all 8 pigs with C3 droplets when using triggered high MI imaging and in 5 of 6 pigs that had 1.7 MHz real time-high MI imaging. Although quantitative myocardial contrast was lower with real-time high MI imaging than 1:1 triggering, the correlation between real-time resting defect size and infarct size was good (r=0.97; P<0.001), as was the correlation with number of transmural infarcted segments by delayed enhancement imaging.
CONCLUSIONS: Targeted transthoracic acoustic activation of infused intravenous C3 nanodroplets is effective, resulting in echogenic and persistent microbubbles which provide real-time high MI visualization of perfusion defects.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  acoustic activation; angiography; echocardiography; fluorocarbons; perfusion

Mesh:

Substances:

Year:  2016        PMID: 26712160      PMCID: PMC4697280          DOI: 10.1161/CIRCIMAGING.115.003770

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  17 in total

1.  Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons.

Authors:  Paul S Sheeran; Samantha H Luois; Lee B Mullin; Terry O Matsunaga; Paul A Dayton
Journal:  Biomaterials       Date:  2012-01-29       Impact factor: 12.479

2.  Myocardial capillaries and coronary flow reserve.

Authors:  Sanjiv Kaul; Ananda R Jayaweera
Journal:  J Am Coll Cardiol       Date:  2008-10-21       Impact factor: 24.094

3.  Basis for detection of stenosis using venous administration of microbubbles during myocardial contrast echocardiography: bolus or continuous infusion?

Authors:  K Wei; A R Jayaweera; S Firoozan; A Linka; D M Skyba; S Kaul
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

4.  Ultrasound internal tattooing.

Authors:  Olivier Couture; Magalie Faivre; Nicolas Pannacci; Avin Babataheri; Vincent Servois; Patrick Tabeling; Mickael Tanter
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

5.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion.

Authors:  K Wei; A R Jayaweera; S Firoozan; A Linka; D M Skyba; S Kaul
Journal:  Circulation       Date:  1998-02-10       Impact factor: 29.690

6.  Interactions between microbubbles and ultrasound: in vitro and in vivo observations.

Authors:  K Wei; D M Skyba; C Firschke; A R Jayaweera; J R Lindner; S Kaul
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

7.  On the acoustic properties of vaporized submicron perfluorocarbon droplets.

Authors:  Nikita Reznik; Guillaume Lajoinie; Oleksandr Shpak; Erik C Gelderblom; Ross Williams; Nico de Jong; Michel Versluis; Peter N Burns
Journal:  Ultrasound Med Biol       Date:  2014-01-22       Impact factor: 2.998

8.  Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound.

Authors:  Paul S Sheeran; Samantha Luois; Paul A Dayton; Terry O Matsunaga
Journal:  Langmuir       Date:  2011-07-28       Impact factor: 3.882

9.  Diagnostic ultrasound induced inertial cavitation to non-invasively restore coronary and microvascular flow in acute myocardial infarction.

Authors:  Feng Xie; Shunji Gao; Juefei Wu; John Lof; Stanley Radio; Francois Vignon; William Shi; Jeffry Powers; Evan Unger; E Carr Everbach; Jinjin Liu; Thomas R Porter
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

Review 10.  Phase-change nanoparticles using highly volatile perfluorocarbons: toward a platform for extravascular ultrasound imaging.

Authors:  Terry O Matsunaga; Paul S Sheeran; Samantha Luois; Jason E Streeter; Lee B Mullin; Bhaskar Banerjee; Paul A Dayton
Journal:  Theranostics       Date:  2012-12-23       Impact factor: 11.556

View more
  11 in total

Review 1.  Optimizing Acoustic Activation of Phase Change Contrast Agents With the Activation Pressure Matching Method: A Review.

Authors:  Juan D Rojas; Paul A Dayton
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2016-10-12       Impact factor: 2.725

2.  Phase-Conversion Nanoparticle Contrast Agents: Do Good Things Come in Small Packages?

Authors:  Jonathan R Lindner
Journal:  Circ Cardiovasc Imaging       Date:  2016-01       Impact factor: 7.792

3.  Focused ultrasound-facilitated brain drug delivery using optimized nanodroplets: vaporization efficiency dictates large molecular delivery.

Authors:  Shih-Ying Wu; Samantha M Fix; Christopher B Arena; Cherry C Chen; Wenlan Zheng; Oluyemi O Olumolade; Virginie Papadopoulou; Anthony Novell; Paul A Dayton; Elisa E Konofagou
Journal:  Phys Med Biol       Date:  2018-01-22       Impact factor: 3.609

Review 4.  Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials.

Authors:  Soufiane El Kadi; Thomas R Porter; Niels J W Verouden; Albert C van Rossum; Otto Kamp
Journal:  JACC Cardiovasc Imaging       Date:  2021-10-13

5.  Acoustic Detection of Retained Perfluoropropane Droplets Within the Developing Myocardial Infarct Zone.

Authors:  Ping Zeng; Cheng Chen; John Lof; Elizabeth Stolze; Shouqiang Li; Xucai Chen; John Pacella; Flordeliza S Villanueva; Terry Matsunaga; E Carr Everbach; Hongwen Fei; Feng Xie; Thomas Porter
Journal:  Ultrasound Med Biol       Date:  2022-08-30       Impact factor: 3.694

6.  Selective Enhancement of Swine Myocardium with a Novel Ultrasound Enhancing Agent During Transthoracic Echocardiography.

Authors:  Michael Cimorelli; Michael A Flynn; Brett Angel; Emily Reimold; Sahil S Banka; Benjamin Andrien; Aaron Fafarman; Richard Huneke; Andrew Kohut; Steven Wrenn
Journal:  J Cardiovasc Transl Res       Date:  2022-01-31       Impact factor: 3.216

7.  Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro.

Authors:  Joseph P Marshalek; Paul S Sheeran; Pier Ingram; Paul A Dayton; Russell S Witte; Terry O Matsunaga
Journal:  J Control Release       Date:  2016-09-26       Impact factor: 9.776

8.  Delayed Echo Enhancement Imaging to Quantify Myocardial Infarct Size.

Authors:  Ping Zeng; Lijun Qian; John Lof; Elizabeth Stolze; Soufiane El Kadi; Thomas Bargar; Jiri Sklenar; Terry Matsunaga; Feng Xie; Thomas R Porter
Journal:  J Am Soc Echocardiogr       Date:  2021-03-09       Impact factor: 7.722

9.  Selective infarct zone imaging with intravenous acoustically activated droplets.

Authors:  Songita A Choudhury; Feng Xie; Shelby Kutty; John Lof; Elizabeth Stolze; Thomas R Porter
Journal:  PLoS One       Date:  2018-12-14       Impact factor: 3.240

Review 10.  Utilization of diagnostic ultrasound and intravenous lipid-encapsulated perfluorocarbons in non-invasive targeted cardiovascular therapeutics.

Authors:  Thomas R Porter; Songita A Choudhury; Feng Xie
Journal:  J Ther Ultrasound       Date:  2016-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.